News / Taiwan / economic_daily
San Fu Biotech Secures Global Rights for Ainos' Oral Interferon Drug
Health Technology · Biotechnology · economic_daily · 2026-10-13
4755
San Fu Biotech has signed a licensing deal with Nasdaq-listed Ainos to develop and commercialize the oral interferon drug VELDONA for two indications.
What Happened
Strategic Licensing Agreement: San Fu Biotech, a subsidiary of San Fu Chemical, has signed a licensing agreement with Nasdaq-listed Ainos, Inc. to acquire global development, manufacturing, and commercialization rights for the low-dose oral interferon drug VELDONA. The deal covers two specific indications and grants San Fu Biotech a right of first refusal for 15 additional indications.
Targeting Key Indications: The licensed indications include Sjögren's syndrome (dry eye/mouth syndrome) and thrombocytopenia. Notably, the treatment for Sjögren's syndrome has already completed Phase II/III clinical trials in the United States, providing a solid foundation for further development.
Addressing Medical Needs: Sjögren's syndrome is a chronic autoimmune disease where the immune system attacks exocrine glands, causing severe dryness. By securing these rights, San Fu Biotech aims to address significant unmet medical needs and expand its footprint in the global pharmaceutical market.
Financial Terms: Under the agreement, San Fu Biotech will pay an upfront licensing fee to Ainos, with future obligations including milestone payments and revenue sharing for any potential sub-licensing activities. This partnership represents a significant milestone for San Fu Biotech's expansion into the biotechnology sector.